0000000000530655

AUTHOR

Tanios Bekaii-saab

showing 2 related works from this author

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).

2021

348 Background: The proportion of females in medicine is increasing (approx. 50% in medical school/workforce), but disparities in female authorship in oncology research publications exist; female corresponding authorship reportedly ranges from 7.2-39.1% in oncology clinical trials (Ludmir et al 2019). This study aimed to describe and assess factors associated with female first and senior authorship in later phase systemic clinical trials in BTC and to identify any changes over time. Methods: Embase/Medline were used to identify final primary trial publications in BTC (2000-2020) (excluding phase I (PI) (expected to move to later phase), mixed tumour site trials, reviews, editorials and tri…

Clinical trialCancer Researchmedicine.medical_specialtyBiliary tract cancerOncologybusiness.industryFamily medicineWorkforceRepresentation (systemics)Medical schoolMedicinebusinessJournal of Clinical Oncology
researchProduct

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

2015

BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.METHODS: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using…

Oncologymedicine.medical_specialtyDisease-Free SurvivalCholangiocarcinoma03 medical and health sciencesAdvanced diseaseCisplatin and gemcitabine0302 clinical medicineInternal medicinemedicineJournal ArticleHumansProgression-free survivalProportional Hazards ModelsPerformance statusReceiver operating characteristicManchester Cancer Research Centrebusiness.industryProportional hazards modelResearch Support Non-U.S. Gov'tResearchInstitutes_Networks_Beacons/mcrcHazard ratioArea under the curveCancerHematologymedicine.diseasePrognosisConfidence intervalSurgeryTreatment OutcomeOncologyBile Duct NeoplasmsROC Curve030220 oncology & carcinogenesisABC-02Multivariate AnalysisBiliary tract cancer030211 gastroenterology & hepatologybusinessPerformance statusPrognostic modelMeta-Analysis
researchProduct